John Zalcberg
John Zalcberg
Verified email at
TitleCited byYear
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
CS Karapetis, S Khambata-Ford, DJ Jonker, CJ O'Callaghan, D Tu, ...
New England Journal of Medicine 359 (17), 1757-1765, 2008
Cetuximab for the treatment of colorectal cancer
DJ Jonker, CJ O'Callaghan, CS Karapetis, JR Zalcberg, D Tu, HJ Au, ...
New England Journal of Medicine 357 (20), 2040-2048, 2007
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij, PG Casali, J Zalcberg, A LeCesne, P Reichardt, JY Blay, ...
The Lancet 364 (9440), 1127-1134, 2004
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo …
CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ...
The Lancet 383 (9911), 31-39, 2014
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis
KM Sjoquist, BH Burmeister, BM Smithers, JR Zalcberg, RJ Simes, ...
The lancet oncology 12 (7), 681-692, 2011
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis
V Gebski, B Burmeister, BM Smithers, K Foo, J Zalcberg, J Simes, ...
The lancet oncology 8 (3), 226-234, 2007
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
GD Demetri, RS Benjamin, CD Blanke, JY Blay, P Casali, H Choi, ...
Journal of the National Comprehensive Cancer Network: JNCCN 5, S1-29; quiz S30, 2007
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
M Debiec-Rychter, R Sciot, A Le Cesne, M Schlemmer, P Hohenberger, ...
European journal of cancer 42 (8), 1093-1103, 2006
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ...
Jama 304 (16), 1812-1820, 2010
Delivering affordable cancer care in high-income countries
R Sullivan, J Peppercorn, K Sikora, J Zalcberg, NJ Meropol, E Amir, ...
The lancet oncology 12 (10), 933-980, 2011
Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation …
SY Ngan, B Burmeister, RJ Fisher, M Solomon, D Goldstein, D Joseph, ...
J Clin Oncol 30 (31), 3827-33, 2012
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
JR Zalcberg, J Verweij, PG Casali, A Le Cesne, P Reichardt, JY Blay, ...
European Journal of Cancer 41 (12), 1751-1757, 2005
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III …
NC Tebbutt, K Wilson, VJ Gebski, MM Cummins, D Zannino, ...
Journal of Clinical Oncology 28 (19), 3191-3198, 2010
Randomized trial of coordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with cancer
SA McLachlan, A Allenby, J Matthews, A Wirth, D Kissane, M Bishop, ...
Journal of Clinical Oncology 19 (21), 4117-4125, 2001
Final results of a randomised trial comparing ‘Tomudex’(raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
D Cunningham, JR Zalcberg, U Rath, I Oliver, E Van Cutsem, C Svensson, ...
Annals of oncology 7 (9), 961-965, 1996
Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation
A El-Osta, P Kantharidis, JR Zalcberg, AP Wolffe
Molecular and cellular biology 22 (6), 1844-1857, 2002
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive …
RL Basser, JEJ Rasko, K Clarke, J Cebon, MD Green, AP Grigg, ...
Blood 89 (9), 3118-3128, 1997
Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs
EK Baker, RW Johnstone, JR Zalcberg, A El-Osta
Oncogene 24 (54), 8061, 2005
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
JD Mellor, MP Brown, HR Irving, JR Zalcberg, A Dobrovic
Journal of hematology & oncology 6 (1), 1, 2013
An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin
RW Tothill, A Kowalczyk, D Rischin, A Bousioutas, I Haviv, RK Van Laar, ...
Cancer research 65 (10), 4031-4040, 2005
The system can't perform the operation now. Try again later.
Articles 1–20